

## REMARKS

### Status

Claims 11-17 are pending in this application.

### Response to Election/Restrictions

The Examiner has required restriction in the above-identified application and has divided the claims as follows:

Group I—Claims 1-10, drawn to a method of treating thrombosis, comprising administering to a patient a pharmaceutical composition comprising a small organic compound.

Group II—Claims 11-17, drawn to a method of inhibiting Factor XIa by administering a small organic compound.

Applicants have elected Group II, Claims 11-17, for examination purposes only. Applicants have elected the species of Example 1 for examination purposes. Applicants respectfully request that, should the Examiner find the elected species allowable, the search be extended, since Applicants are entitled to consideration of claims to a reasonable number of disclosed species in addition to the elected species as provided for under 37 CFR 1.146.

In view of the foregoing, Applicants submit that the application is now in condition for examination on the merits. Early notification of such action is earnestly solicited. If the Examiner has any questions or believes further discussion will aid examination and advance prosecution of the application, a telephone call to the undersigned is invited.

Respectfully submitted,

Date: October 26, 2006

/jing g. sun/  
Jing G. Sun, Ph.D.  
Registration No. 45,914  
Telephone No. (609) 252-3791  
Facsimile No. (609) 252-4526

**Please forward all future written correspondence relating to this application to:**

Louis J. Wille  
Patent Department  
Bristol-Myers Squibb Company  
P.O. Box 4000  
Princeton, NJ 08543-4000